Viking Therapeutics (NASDAQ:VKTX – Get Free Report) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01, Briefing.com reports. During the same quarter in the previous year, the company posted ($0.25) EPS.
Viking Therapeutics Trading Up 7.9 %
VKTX stock opened at $74.31 on Friday. Viking Therapeutics has a 12-month low of $8.28 and a 12-month high of $99.41. The company has a 50 day moving average of $68.35 and a two-hundred day moving average of $34.79.
Insider Transactions at Viking Therapeutics
In other Viking Therapeutics news, CEO Brian Lian sold 35,000 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $23.95, for a total value of $838,250.00. Following the completion of the sale, the chief executive officer now directly owns 2,264,882 shares of the company’s stock, valued at approximately $54,243,923.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Sarah Kathryn Rouan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Brian Lian sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $23.95, for a total transaction of $838,250.00. Following the transaction, the chief executive officer now directly owns 2,264,882 shares of the company’s stock, valued at $54,243,923.90. The disclosure for this sale can be found here. Insiders have sold a total of 329,079 shares of company stock worth $8,769,653 in the last 90 days. 4.70% of the stock is owned by insiders.
Analysts Set New Price Targets
View Our Latest Research Report on Viking Therapeutics
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
- Five stocks we like better than Viking Therapeutics
- The How and Why of Investing in Biotech Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Stocks Leading the U.S. Agriculture Comeback
- About the Markup Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.